Phase 3 Readout

RPRX: Phase 3 Topline: A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermitte

Name: Phase 3 Topline: A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermitte
Start: 2028-10-12
End: 2028-10-12

October 12, 2028 · apalutamide. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 12, 2028
Company: Royalty Pharma plc (RPRX)
Drug: apalutamide

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermitte

October 12, 2028

RPRX overview →

Company: Royalty Pharma plc (RPRX)
Drug: apalutamide
Indication: Metastatic Castrate-sensitive Prostate Cancer